Skip to main content
Article thumbnail
Location of Repository

MicroRNA: an Emerging Therapeutic Target and Intervention Tool

By Zhen Liu, Alhousseynou Sall and Decheng Yang


MicroRNAs (miRNAs) are a class of short non-coding RNAs with posttranscriptional regulatory functions. To date, more than 600 human miRNAs have been experimentally identified, and estimated to regulate more than one third of cellular messenger RNAs. Accumulating evidence has linked the dysregulated expression patterns of miRNAs to a variety of diseases, such as cancer, neurodegenerative diseases, cardiovascular diseases and viral infections. MiRNAs provide its particular layer of network for gene regulation, thus possessing the great potential both as a novel class of therapeutic targets and as a powerful intervention tool. In this regard, synthetic RNAs that contain the binding sites of miRNA have been shown to work as a “decoy” or “miRNA sponge” to inhibit the function of specific miRNAs. On the other hand, miRNA expression vectors have been used to restore or overexpress specific miRNAs to achieve a long-term effect. Further, double-stranded miRNA mimetics for transient replacement have been experimentally validated. Endogenous precursor miRNAs have also been used as scaffolds for the induction of RNA interference. This article reviews the recent progress on this emerging technology as a powerful tool for gene regulation studies and particularly as a rationale strategy for design of therapeutics

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets.
  2. (2005). A cellular microRNA mediates antiviral defense in human cells. Science
  3. (2007). A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha.
  4. (2005). A human, ATP-independent, RISC assembly machine fueled by pre-miRNA.
  5. (2005). A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.
  6. (2002). A microRNA in a multiple-turnover RNAi enzyme complex. Science
  7. (2005). A microRNA polycistron as a potential human oncogene. Nature
  8. (2005). A MicroRNA signature associated with prognosis and progression in chronic lymphocytic
  9. (2007). A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood
  10. (2005). A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res.
  11. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science
  12. A versatile approach to multiple gene RNA interference using microRNA-based short hairpin RNAs.
  13. (2003). Activation of the interferon system by short-interfering RNAs.
  14. (2008). Advances in microRNAs: implications for gene therapists.
  15. (2007). Altered microRNA expression in human heart disease.
  16. (2005). An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucl. Acids Res.
  17. (2000). An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells.
  18. (2008). Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nuc. Acids Res.
  19. (2005). Antisense-mediated depletion reveals essential and specific functions of microRNAs in Drosophila development. Cell
  20. (2001). Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
  21. (2007). Artificial microRNA-mediated virus resistance in plants.
  22. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.
  23. (2008). biology and therapeutic potential of RNA interference, microRNA and antagomirs.
  24. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA.
  25. (2002). Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells.
  26. (1999). Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.
  27. (2005). Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus.
  28. (2007). Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucl. Acids Res.
  29. (2006). Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene.
  30. (2008). Conditional gene silencing in mammalian cells mediated by a stress-inducible promoter.
  31. (2004). Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett.
  32. (2006). Conserved microRNA characteristics in mammals. Oligonucleotides
  33. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell
  34. (2007). Construction and identification of a human liver specific microRNA eukaryotic expression vector.
  35. (2005). Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation.
  36. (2003). Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative target genes. Nucl. Acids Res.
  37. (1983). Dispersion of the ras family of transforming genes to four different chromosomes in man. Nature
  38. (2007). Double-stranded regions are essential design components of potent inhibitors of RISC function. RNA
  39. (2007). duplex degradation and subcellular localization of antagomirs. Nucl. Acids Res.
  40. (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer.
  41. (2004). Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucl. Acids Res.
  42. (2004). Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA
  43. (2003). Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs.
  44. (2007). Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood
  45. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature
  46. (2002). Frequent deletions and down-regulation of micro-
  47. (2008). Gene silencing in plants using artificial microRNAs and other small RNAs.
  48. (2002). Gene silencing using micro-RNA designed hairpins. RNA
  49. (2004). High expression of precursor
  50. (2008). Highly specific gene silencing by artificial miRNAs in rice. PLoS ONE
  51. (2004). Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.
  52. (2003). Human let-7 stem-loop precursors harbor features of RNase III cleavage products. Nucl. Acids Res.
  53. (2004). Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA
  54. (2003). Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood
  55. (2004). Identification of mammalian microRNA host genes and transcription units. Genome Res.
  56. (2005). Identification of microRNAs of the herpesvirus family.
  57. (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis.
  58. (2006). Implications of micro-RNA profiling for cancer diagnosis. Oncogene.
  59. (2006). Improved targeting of miRNA with antisense oligonucleotides. Nucl. Acids Res.
  60. (2003). Induction of an interferon response by RNAi vectors in mammalian cells.
  61. (2005). Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice.
  62. (2007). Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters.
  63. (2003). Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization. Curr. Eye Res.
  64. (2006). Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection.
  65. (2006). LNA-modified oligonucleotides mediate specific inhibition of microRNA function.
  66. (2007). Locked nucleic acid oligonucleotides: the next generation of antisense agents? BioDrugs
  67. (2005). Making sense of antisense.
  68. (2005). MicroRNA biogenesis: coordinated cropping and dicing.
  69. (2006). MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical
  70. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res.
  71. (2004). MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.
  72. (2007). MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells.
  73. (2007). MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy.
  74. (2007). microRNA: an Emerging Therapeutic. ChemMedChem.
  75. (2003). MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms.
  76. microRNAs as oncogenes and tumor suppressors.
  77. (2006). microRNAs exhibit high frequency genomic alterations in human cancer.
  78. (2007). MicroRNAs in disease and potential therapeutic applications.
  79. (2007). MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation
  80. (2007). MicroRNAs play an essential role in the development of cardiac hypertrophy.
  81. (2006). MicroRNAs: a new class of regulatory genes affecting metabolism.
  82. (2008). microRNAs: a new emerging class of players for disease diagnostics and gene therapy.
  83. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.
  84. (2004). miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol.
  85. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2.
  86. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science
  87. (2000). Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucl. Acids Res.
  88. (2006). Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell
  89. (2007). Molecular therapy in the microRNA era.
  90. (2007). Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4.
  91. (2004). Nuclear export of microRNA precursors.
  92. (2006). Off-target effects by siRNA can induce toxic phenotype. RNA
  93. (2006). Plant microRNA: a small regulatory molecule with big impact.
  94. (2006). Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucl. Acids Res.
  95. (2005). Positional effect of chemical modifications on short interference RNA activity in mammalian cells.
  96. (2006). Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma
  97. (2005). Principles of microRNA-target recognition. PLoS Biol.
  98. (2003). Progress and problems with the use of viral vectors for gene therapy.
  99. (2007). Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell. Biol.
  100. (2007). RNA in brain disease: no longer just "the messenger in the middle".
  101. (2002). RNA interference in adult mice.
  102. (2006). RNA polymerase III transcribes human microRNAs.
  103. (2006). RNAi-mediated gene silencing in non-human primates.
  104. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.
  105. (2005). Second-generation shRNA libraries covering the mouse and human
  106. (2004). Sequence-specific inhibition of microRNAand siRNA-induced RNA silencing. RNA
  107. (2004). Sequence-specific inhibition of small RNA function. PLoS Biol.
  108. (2003). Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucl. Acids Res.
  109. (2006). Short RNAs repress translation after initiation in mammalian cells.
  110. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature
  111. (2003). siRNA function in RNAi: a chemical modification analysis. RNA
  112. (2003). siRNAs can function as miRNAs. Genes Dev.
  113. (2004). Small interfering RNA-induced transcriptional gene silencing in human cells. Science
  114. (2005). Specific and potent RNAi in the nucleus of human cells.
  115. (2005). Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor
  116. (2005). Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats. Neuroscience
  117. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucl. Acids Res.
  118. (2005). Suppression of RNA interference by adenovirus virus-associated
  119. (2005). SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature
  120. (2007). Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR.
  121. (2006). The expression profile of microRNAs in mouse embryos. Nucl. Acids Res.
  122. (1999). The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation.
  123. (2003). The nuclear RNase III Drosha initiates microRNA processing. Nature
  124. (2005). The role of microRNA genes in papillary thyroid carcinoma.
  125. (2007). The role of microRNAs in cancer: no small
  126. (2006). The role of PACT in the RNA silencing pathway.
  127. (2005). The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science
  128. (2007). Therapeutic potential for microRNAs.
  129. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.
  130. (2001). Thirty-three years later, a glimpse at the ribonuclease III active site.
  131. (2007). Tissue-specific and reversible RNA interference in transgenic
  132. (2004). Transcription and processing of human microRNA precursors.
  133. (2005). TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature
  134. (2002). U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells.
  135. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell.
  136. (2005). Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol.
  137. (2007). virus-free, and inducible RNAi in embryonic stem cells.
  138. (2006). Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.